Source: PiaCenza24 Author: FPG

Home anti-Covid therapy with Hcl: solution to lockdown found. Solution already active in Piedmont. And from the scientific community comes an appeal to Bonaccini. “In fact, a treatment protocol similar to the Piedmontese one was carried out in Rimini in April – with 350 patients treated at home with HCL (hydroxychloroquine) and monitored by 58 GPs. The results? Only 16 patients had to be hospitalized. So why not apply it to the Emilia Romagna region as well? ”.

The solution to avoid the lockdown and avoid losing thousands of jobs and clogging hospitals exists. On Wednesday 11 November the news came that the Piedmont Region approved the experimental protocol called “Covi a casa” which provides for the timely treatment at home with hydroxychloroquine for all those patients who have fever and symptoms related to the Sars-Covid 19 virus (cough, loss of taste, diarrhea …) without having to resort to hospital treatment, but informing the general practitioner.

“Good news, relegated to regional news but it gives us good hope for a radical change in the assessment of the restrictive measures that are being implemented at the national level to stem the” second wave “of the Covid pandemic – 19 and the spectrum of other months of total closure. A closure that we cannot afford at an economic and health level. “

This is what Professor Alessandro Capucci from Bologna, an international expert in cardiovascular diseases, formerly Director of the Postgraduate School of Cardiovascular Diseases of the Marche Polytechnic University in Ancona, says. 

Capucci is the first signatory and speaker of the scientific work derived from the treatment protocol carried out in April in the Rimini area on 350 patients who were treated at home by 58 general practitioners.

The study (carried out in April and published in June in the prestigious Italian Federation of Cardiology journal) “Low hospitalization rate without severe arrhytmias: a prospective survey on 350 patients early home treated with hydroxycloroquine during Covid-19 Pandemic *” wanted to demonstrate that Covid, if treated immediately (at the first fever and the first symptoms) with HCQ and possibly with Azithromycin, not only healed within a week, but also did not show collateral damage.

These are the very comforting results: out of 350 treated patients, 76 of these were treated with a combination of HCQ and Azithromycin.

Of the 274 patients treated with hydroxychloroquine alone, 16 patients entered the hospital (5.8%) but not in the ICU! Another small number of patients (2.9%) experienced minor complications such as diarrhea or gastrointestinal disturbances ; but no one had to stop in treatment and no cardiological damage was found.

Of the 76 patients treated with the combination of azithromycin and hydroxychloroquine, hospitalization was arranged for 4 s (5.2%) ; while only 2 patients recorded minor complications (2.6%). No patient had problems with syncope, arrhythmias or sudden death.

What does all this mean? 

Despite the fact that AIFA still does not recommend the use of hydroxychloroquine (due to interpretations of results of late uses), clinicians have been able to field test the effectiveness of prompt treatment. In addition to the fact that it is possible to treat the sick from home, without aggravating their conditions if taken to hospital, and without making hospitals useless lazarets, precluding beds and ICU places for all other subjects suffering from pathologies with a high rate of mortality (tumors, leukemia, sudden deaths, ischemias, various traumas etc etc).

The appeal of the clinicians to the President of Emilia Romagna, Stefano Bonaccini and to the Councilor for Health Policies, Raffaele Donini, is to follow the example of the Piedmont Region which since yesterday has prepared the activation of the care at home to avoid the risk of a total closure of the activities of the Region.

“As a clinician and as a cardiologist, the management of Covid – 19 here in Italy scares me a lot. We must carefully evaluate the impact that these restrictions have on the health of all the millions of citizens who from March to today have had to renounce to seek treatment to make room for patients with the virus whose mortality is reduced and refers above all to subjects with multiple pathologies and over the age of 80. – declares Professor Capucci. 

In terms of costs for the community, the cost of a general practitioner affiliated with the NHS and adequately equipped and informed is undoubtedly lower than a bed both in hospital and even more so in intensive care. The numbers speak for themselves, but you have to know how to read them. The protocols are now proven.

We turn to the authorities of our region to ensure that common sense prevails in clinical research which demonstrates, without proof of denial, because it is tested on the territory, that the virus can be treated from home promptly, effectively and without collateral damage. “

Related: HCQ is effective for COVID-19 when used early: analysis of 132 studies

How hydroxychloroquine works at the cellular level

COVID-19 outpatients – early risk-stratified treatment with zinc plus low dose hydroxychloroquine and azithromycin: a retrospective case series study

Italy study: A new look at safety with hydroxychloroquine in COVID-19

In 2003, the effects of chloroquine/HCQ on viral infections were known: an old drug pitted against SARS and HIV

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

Stark madness to ban ivermectin

Buried in the note is the real reason for making ivermectin inaccessible – the fear that persons taking it ‘may elect not to be vaccinated as part of the national Covid-19 vaccination program’. This is outrageous. When someone is infected with Covid, it is too late to bother with vaccination. They need early treatment. To deny it to coerce them into accepting a vaccine, one of whose side-effects is death, is immoral.

Read More »

Australia’s TGA Bans GPs from Prescribing Ivermectin

Australia’s medicine and therapeutic regulatory, the Therapeutic Good Administration (TGA) recently took the gloves off with Ivermectin, the economical anti-parasitic drug associated with at least 63 completed clinical trials involving SARS-CoV-2, the virus behind COVID-19. Now TGA formally places a national prohibition on off-label prescribing of ivermectin to all general practitioners. A comparable move as to what TGA did with hydroxychloroquine in 2020. Clearly further evidence of tightening encroachment of the critically important doctor-patient treatment relationship allowing consent to medical treatment using off-label medications. Of course, this isn’t occurring in a vacuum—it’s part of an unfolding, integrated and what have the signs of a coordinated and orchestrated government action to stop any and all treatments other than those the government declares acceptable.

Read More »